Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Sotio Biotech Inc.
Pfizer
Pfizer
Erasca, Inc.
Solve Therapeutics
Degron Therapeutics Co.
Actym Therapeutics, Inc.
Ikena Oncology
Eli Lilly and Company
Theratechnologies
ABM Therapeutics Corporation
MacroGenics
Fore Biotherapeutics
Celgene
Celgene
Celldex Therapeutics
Valerio Therapeutics
Valerio Therapeutics
Calando Pharmaceuticals
Exelixis
Mannkind Corporation